At #iwCLL2025, Barbara Eichhorst discussed the efficacy of epcoritamab monotherapy in first-line Richter’s transformation, highlighting 2-year follow-up results from the EPCORE CLL-1 trial.
Watch the interview here:
👉 buff.ly/UvDvXD3 👈
#CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
Watch the interview here:
👉 buff.ly/UvDvXD3 👈
#CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky
October 18, 2025 at 3:02 PM
Everybody can reply
New publication 📝 Phase III results, published in Blood, show acalabrutinib + obinutuzumab significantly improved PFS and OS vs chlorambucil + obinutuzumab in treatment-naïve CLL (72-month PFS, 78.0% vs 17.2%; p < 0.0001).
Learn more: LymphomaHub.com
#CLLsm #leusm #MedNews #MedEd
Learn more: LymphomaHub.com
#CLLsm #leusm #MedNews #MedEd
October 17, 2025 at 8:01 AM
Everybody can reply
🎥 Inga Mandac-Smoljanovic outlines the factors that affect the dose of ibrutinib administered in patients with CLL, highlighting the importance of considering comorbidities & concomitant medications when selecting a dose:
👉 buff.ly/Rs2rluB 👈
#iwCLL2025 #CLLsm #Leusm #Leukemia #HemOnc #MedSky
👉 buff.ly/Rs2rluB 👈
#iwCLL2025 #CLLsm #Leusm #Leukemia #HemOnc #MedSky
October 16, 2025 at 8:29 AM
Everybody can reply
1 likes
🎥 Marta Coscia shares findings from the BRUIN CLL-321 trial investigating pirtobrutinib versus idelalisib plus rituximab or bendamustine + rituximab in patients with CLL/SLL previously exposed to a covalent BTKi:
👉 buff.ly/rBWUBYh 👈
#iwCLL2025 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky
👉 buff.ly/rBWUBYh 👈
#iwCLL2025 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky
October 13, 2025 at 8:29 AM
Everybody can reply
We recently spoke with Krzysztof Jamroziak, who provided valuable insight into the current role of MRD in CLL, highlighting technical aspects and its clinical significance.
Click here to check out the interview:
🎥 buff.ly/20uHc4O
#CLLsm #Leusm #iwCLL2025 #Leukemia #HemOnc #BloodSky #MedSky
Click here to check out the interview:
🎥 buff.ly/20uHc4O
#CLLsm #Leusm #iwCLL2025 #Leukemia #HemOnc #BloodSky #MedSky
October 10, 2025 at 5:03 PM
Everybody can reply
Want to hear about the development of rocbrutinib, a 4th-generation BTK inhibitor, as a potential therapeutic option for BTKi-resistant CLL?🩸
Watch our interview with Britten Gordon from #iwCLL2025:
🎥 buff.ly/eKQamE2
#CLLsm #Leusm #Leukemia #HemOnc #MedSky #BloodSky #HemeSky
Watch our interview with Britten Gordon from #iwCLL2025:
🎥 buff.ly/eKQamE2
#CLLsm #Leusm #Leukemia #HemOnc #MedSky #BloodSky #HemeSky
September 30, 2025 at 5:04 PM
Everybody can reply
1 quotes
1 likes
Want to hear about the safety & efficacy of the CD19-directed CAR-T var-cel (ARI-0001) in patients with CLL or Richter's transformation?💉🩸
Then make sure you watch our interview from #iwCLL2025 with Nil Albiol of @hospitalclinic.bsky.social:
🎥 buff.ly/AnTQebz
#CARTCell #ImmunoOnc #CLLsm #Leusm
Then make sure you watch our interview from #iwCLL2025 with Nil Albiol of @hospitalclinic.bsky.social:
🎥 buff.ly/AnTQebz
#CARTCell #ImmunoOnc #CLLsm #Leusm
September 27, 2025 at 1:02 PM
Everybody can reply
Missed out on #iwCLL2025?🩸
Not to worry! Check out our exclusive coverage of the meeting to catch up on the latest updates and advances in CLL:
👉 buff.ly/GBOkgBn 👈
#CLLsm #Leusm #Leukemia #HemOnc #CTSM #ImmunoOnc
Not to worry! Check out our exclusive coverage of the meeting to catch up on the latest updates and advances in CLL:
👉 buff.ly/GBOkgBn 👈
#CLLsm #Leusm #Leukemia #HemOnc #CTSM #ImmunoOnc
September 26, 2025 at 3:04 PM
Everybody can reply
1 likes
It was great to catch up with @drmdavids.bsky.social of @danafarber.bsky.social at #iwCLL2025!🎥
Hear as Dr Davids introduces the MAVRiC trial, which will investigate a mutation-guided retreatment strategy using the AV regimen in patients with CLL/SLL in the 2L setting:
👉 buff.ly/aouDK9h
#CLLsm
Hear as Dr Davids introduces the MAVRiC trial, which will investigate a mutation-guided retreatment strategy using the AV regimen in patients with CLL/SLL in the 2L setting:
👉 buff.ly/aouDK9h
#CLLsm
September 24, 2025 at 3:03 PM
Everybody can reply
1 quotes
1 likes
Watch our insightful interview from #iwCLL2025, in which Alexey Danilov of @cityofhope.bsky.social discusses the emerging promise of targeted protein degraders in CLL and other heme malignancies:
👉 buff.ly/aDN40ud 👈
#CLLsm #Leusm #Leukemia #HemOnc #MantleCellLymphoma #LYMsm #HemeSky #BloodSky
👉 buff.ly/aDN40ud 👈
#CLLsm #Leusm #Leukemia #HemOnc #MantleCellLymphoma #LYMsm #HemeSky #BloodSky
September 22, 2025 at 4:42 PM
Everybody can reply
1 likes
At #iwCLL2025 last week, we had the pleasure of speaking with Kerry Rogers of @osuhematology.bsky.social to hear about the management of patients with double-refractory CLL.🩸
Watch the interview here:
🎥 buff.ly/ZwOkLWw
#CLLsm #Leusm #Leukemia #HemOnc
Watch the interview here:
🎥 buff.ly/ZwOkLWw
#CLLsm #Leusm #Leukemia #HemOnc
September 20, 2025 at 2:01 PM
Everybody can reply
We had a fantastic time at #iwCLL2025 last week!🇵🇱
Thank you to the organizers for having us on-site, and to the experts who interviewed with us!😊
Check out our exclusive coverage of the event here, with more coming soon:
👉 buff.ly/Fv2j8p4
#CLLsm #Leusm #Leukemia #HemOnc
Thank you to the organizers for having us on-site, and to the experts who interviewed with us!😊
Check out our exclusive coverage of the event here, with more coming soon:
👉 buff.ly/Fv2j8p4
#CLLsm #Leusm #Leukemia #HemOnc
September 19, 2025 at 3:05 PM
Everybody can reply
It's our first day onsite at #iwCLL2025 and we can't wait for two jam-packed days of expert interviews about all things CLL!🩸
Keep an eye on our site over the coming weeks for our exclusive coverage from the event.🎥
👉VJHemOnc.com
#CLLsm #Leusm #Leukemia #BloodSky #MedSky #HemeSky #HemOnc
Keep an eye on our site over the coming weeks for our exclusive coverage from the event.🎥
👉VJHemOnc.com
#CLLsm #Leusm #Leukemia #BloodSky #MedSky #HemeSky #HemOnc
September 13, 2025 at 8:29 AM
Everybody can reply
Today is #WorldLeukemiaDay.🩸
Dive into our disease channels for the latest news & updates in AML, ALL, CLL, CML, & more: 👉 buff.ly/PCXVECQ
Video interviews, podcasts, roundtable discussions, articles – we have it all! 🎥 🗞️ 🎧
#AMLsm #CLLsm #ALLsm #Leusm
Dive into our disease channels for the latest news & updates in AML, ALL, CLL, CML, & more: 👉 buff.ly/PCXVECQ
Video interviews, podcasts, roundtable discussions, articles – we have it all! 🎥 🗞️ 🎧
#AMLsm #CLLsm #ALLsm #Leusm
September 4, 2025 at 3:03 PM
Everybody can reply
The Phase Ib Safe Accelerated Venetoclax Escalation (SAVE) study explored an accelerated dose ramp-up of venetoclax in patients with CLL.
Learn more in our interview with the lovely Jennifer Crombie of @danafarber.bsky.social:
🎥 buff.ly/GzIwSol
#CLLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc
Learn more in our interview with the lovely Jennifer Crombie of @danafarber.bsky.social:
🎥 buff.ly/GzIwSol
#CLLsm #Leusm #Leukemia #CTSM #TrialUpdate #HemOnc
September 1, 2025 at 4:42 PM
Everybody can reply
It's always fantastic to catch up with @drmdavids.bsky.social of @danafarber.bsky.social!😄
At #18ICML, Dr Davids shared insights into the ReVenG trial, evaluating the safety & efficacy of venetoclax plus obinutuzumab retreatment in R/R CLL.
Watch now:
👉 buff.ly/5rzmgND 👈
#CLLsm #Leusm #Leukemia
At #18ICML, Dr Davids shared insights into the ReVenG trial, evaluating the safety & efficacy of venetoclax plus obinutuzumab retreatment in R/R CLL.
Watch now:
👉 buff.ly/5rzmgND 👈
#CLLsm #Leusm #Leukemia
August 28, 2025 at 8:29 AM
Everybody can reply
1 likes
We caught up with Adam Kittai at #EHA2025 to hear about the importance of the recently published consensus guidelines for Richter’s transformation, which aim to improve patient outcomes by unifying management practices & research:
🎥 👉 buff.ly/L4eLhvD
#CLLsm #Leusm #HemOnc #BloodSky #HemeSky
🎥 👉 buff.ly/L4eLhvD
#CLLsm #Leusm #HemOnc #BloodSky #HemeSky
August 26, 2025 at 7:01 AM
Everybody can reply
At #ICML18, Alexey Danilov of @cityofhope.bsky.social shared the promising results of a Phase I study evaluating bexobrutideg, a BTK degrader, in R/R CLL resistant to BTK inhibitors.
Watch the interview here:
🎥 buff.ly/cHVydMw
#CLLsm #Leusm #CTSM #TrialUpdate #HemOnc #BloodSky #HemeSky #MedSky
Watch the interview here:
🎥 buff.ly/cHVydMw
#CLLsm #Leusm #CTSM #TrialUpdate #HemOnc #BloodSky #HemeSky #MedSky
August 15, 2025 at 4:42 PM
Everybody can reply
Want to hear insights into the real-world effectiveness of covalent BTK inhibitors in the first-line treatment of patients with symptomatic CLL?🩸
Check out our fantastic recent interview from #18ICML with Ryan Jacobs:
👉 buff.ly/7eXwIqV 👈
#CLLsm #Leusm #HemOnc #BloodSky #HemeSky #MedSky
Check out our fantastic recent interview from #18ICML with Ryan Jacobs:
👉 buff.ly/7eXwIqV 👈
#CLLsm #Leusm #HemOnc #BloodSky #HemeSky #MedSky
August 6, 2025 at 4:06 PM
Everybody can reply
1 likes
Hear about the impact of venetoclax-based therapies on autoimmune cytopenias in patients with CLL from Candida Vitale, who outlines the findings of a retrospective multicenter study conducted by ERIC:
👉 buff.ly/BSjKgtB
#CLLsm #Leusm #Leukemia #HemOnc #EHA2025 #BloodSky #HemeSky #MedSky
👉 buff.ly/BSjKgtB
#CLLsm #Leusm #Leukemia #HemOnc #EHA2025 #BloodSky #HemeSky #MedSky
July 16, 2025 at 1:05 PM
Everybody can reply
It was a pleasure to catch up with @chancheah.bsky.social at #EHA2025 to hear the updated Phase I results of sonrotoclax plus zanubrutinib in patients with R/R CLL/SLL.🩸
Watch the interview here:
👉 buff.ly/TYQfq4h 👈
#CLLsm #Leusm #LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky #HemOnc
Watch the interview here:
👉 buff.ly/TYQfq4h 👈
#CLLsm #Leusm #LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky #HemOnc
June 25, 2025 at 10:02 AM
Everybody can reply
1 reposts
1 likes
Research presented at #ASCO25 highlighted potential treatments for patients with CLL and SLL, including high-risk patients and those with disease that is resistant to BTK inhibitors or degraders. #lymsm #CLLsm shorturl.at/1TJp0
ASCO 2025: Advances in CLL
Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory CLL/SLL.
shorturl.at
June 20, 2025 at 3:23 PM
Everybody can reply